Baycrest’s Goal Management Training Now Offered Through Telus Health’s AbilitiCBT Platform
First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the...
Brain
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19,...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company...
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023...
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a...
$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development...
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision...
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic...
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
Eric Lonnqvist as Chief Financial Officer, Vasu Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations Officer bolster...
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancersSYDNEY, Australia, April...
Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685
MS, Stroke and mmTBI Cover Broader Set of Indications Across North American MarketsNEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) --...
Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session
- Data highlight favorable preclinical profiles for two chemically-distinct allosteric, oral small molecule KRAS inhibitors with potent anti-tumor activity -...